A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Estetrol (Primary)
- Indications Vasomotor symptoms
- Focus Therapeutic Use
- Acronyms E4 RELIEF
- Sponsors Donesta Bioscience
- 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2017 Planned end date changed from 1 Dec 2016 to 1 Feb 2018.
- 08 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2018.